Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Ticagrelor

CAS No.

274693-27-5

Innovator/marketer

Brilinta, Brilique

Polymorphic form

Form II

Therapeutic Area

Blood & blood forming organs

Status

Pipeline

EU DMF readiness

US DMF readiness

028674

Drug description:

Ticagrelor is an antiplatelet agent.
Ticagrelor co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.
It is formulated as tablets, film-coated tablets for oral route of administration.

Mechanism of action:

Ticagrelor is a platelet ADP P2Y12 receptor antagonist. It helps to prevent the formation of blood clots and reduces the occurrence of thrombotic events in acute coronary syndromes (ACS). ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes. The drug candidate is also acts by preventing adenosine from being cleared from the blood stream and by marginally increasing the levels of immune cell activity.

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK